Table 2.
Longitudinal Trends of Key Outcome Measures Throughout the Study
| Variable | Baseline | 8 Wk | 16 Wk | 24 Wk | Rate of Change (Slope)/wk | P Value |
|---|---|---|---|---|---|---|
| VEGF-D, pg/mL | 617 (489-677), n = 25 | 543 (455-704), n = 23 | 581 (485-724), n = 20 | 575 (448-673), n = 22 | –4.53 (–7.56 to –1.5) | .004 |
| FEV1, L | 1.74 (1.46-2.3), n = 25 | 1.98 (1.4-2.36), n = 23 | 2.01 (1.18-2.57), n = 17 | 1.94 (1.2-2.59), n = 18 | –0.0029 (–0.0052 to –0.0006) | .013 |
| FVC, L | 3.08 (2.84-3.94), n = 25 | 3.04 (2.83-3.81), n = 23 | 3.17 (2.6-3.87), n = 17 | 3.36 (2.64-3.93), n = 18 | –0.0019 (–0.004 to 0.0001) | .064 |
| Dlco, mL/mm Hg/min | 14.68 (10.15-16.81), n = 23 | NA | NA | 13.24 (9.25-17.07), n = 18 | –0.01 (–0.054 to 0.034) | .635 |
| SOBQ | 29 (21-35), n = 25 | 31 (16-44), n = 24 | 23 (15-42), n = 21 | 22 (12-40), n = 23 | –0.075 (–0.25 to 0.097) | .386 |
| EQVAS | 80 (65-85), n = 24 | 85 (75-90), n = 23 | 90 (75-95), n = 21 | 90 (80-90), n = 23 | 0.21 (0.016-0.41) | .035 |
| SGRQ | 42 (39-46), n = 25 | 43.5 (38-49), n = 24 | 43 (40-49), n = 22 | 42 (39-47), n = 23 | –0.024 (–0.21 to 0.16) | .797 |
| ATAQ-LAM | 72 (54-88), n = 25 | 70 (49-101), n = 24 | 60 (44-82), n = 22 | 57 (47-84), n = 23 | –0.33 (–0.57 to –0.086) | .009 |
| Sirolimus troughs, ng/mL | 6.3 (4.6-7.6), n = 25 | 5.4 (4-7.5), n = 23 | 7.2 (3.4-9.1), n = 22 | 6.9 (3.4-8.5), n = 22 | 0.026 (–0.042 to 0.093) | .450 |
Data are presented as median (95% CI). ATAQ-LAM = A Tool to Assess Quality of Life in LAM [lymphangioleiomyomatosis]; Dlco = diffusion capacity of the lungs for carbon monoxide; EQVAS = EuroQol visual analog scale; NA = not assessed; SGRQ = St. George’s Respiratory Questionnaire; SOBQ = University of California, San Diego, Shortness of Breath Questionnaire; VEGF-D = vascular endothelial growth factor D.